Brilliant Violet 421™ anti-mouse CD45 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse thymus or spleen

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation³, complement-dependent cytotoxicity^1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)^4,6, Western blotting⁷, and spatial biology (IBEX)^10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
8. Liu F, et al. 2012. Blood. 119:3295. PubMed
9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
2. Balood M, et al. 2022. Nature. 611:405. PubMed
3. Millar FR, et al. 2022. Cell Rep. 41:111596. PubMed
4. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
5. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
6. Pariury H, et al. 2023. Haematologica. :. PubMed
7. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
8. Gomez-Salinero JM, et al. 2022. Cell Stem Cell. 29:593. PubMed
9. Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed
10. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
11. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
12. Schlecht A, et al. 2021. Int J Mol Sci. 22:. PubMed
13. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
14. Naito H, et al. 2020. Nature Protocols. 15(3):1066-1081. PubMed
15. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
16. Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed
17. Gómez-Salinero JM, et al. 2022. Nat Cardiovasc Res. 1:882. PubMed
18. Ando M, et al. 2021. Cancer Res Commun. 1:41. PubMed
19. Takimoto Y, et al. 2023. iScience. 26:106220. PubMed
20. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
21. Willows JW, et al. 2023. iScience. 26:106189. PubMed
22. Chung KJ, et al. 2023. Int J Mol Sci. 24:. PubMed
23. Cui W, et al. 2023. J Exp Med. 220:. PubMed
24. Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed
25. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
26. Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed
27. Ulland TK et al. 2017. Cell. 170(4):649-663 . PubMed
28. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
29. Galán-Díez M, et al. 2022. Cancer Discov. . PubMed
30. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
31. Deng J, et al. 2021. JCI Insight. 6:146133. PubMed
32. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
33. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
34. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
35. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
36. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
37. Karlsson J, et al. 2021. Adv Funct Mater. 31:. PubMed
38. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
39. Song WM, et al. 2018. J Exp Med. 215:745. PubMed
40. Shmeleva EV, et al. 2019. Front Immunol. 10:1780. PubMed
41. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
42. Cui Z, et al. 2022. Bone Res. 10:58. PubMed
43. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
44. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
45. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
46. Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed
47. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
48. Schlecht A, et al. 2021. Front Cell Dev Biol. 8:618598. PubMed
49. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
50. Bell BJ, et al. 2022. Brain Behav Immun Health. 23:100478. PubMed
51. Helm M, et al. 2022. Life (Basel). 12:. PubMed
52. Nishiga Y, et al. 2022. Nat Cancer. 3:1351. PubMed
53. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
54. Saika A, et al. 2020. FASEB Bioadv. 2:59. PubMed
55. Suter EC, et al. 2021. Cell Reports. 36(8):109587. PubMed
56. Mittal S, et al. 2016. Stem Cell Reports. 7:583-590. PubMed
57. Kramann R, et al. 2018. JCI Insight. 3. PubMed
58. Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed
59. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
60. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
61. Chu C, et al. 2016. Dis Model Mech. 9: 473-481. PubMed
62. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
63. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
64. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
65. Li Q, et al. 2019. Front Cell Neurosci. 12:520. PubMed
66. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
67. Agalave NM, et al. 2021. Front Immunol. 12:642420. PubMed
68. Li J, et al. 2020. Elife. 9:00. PubMed
69. Katara GK, et al. 2020. Mol Oncol. 0.729861111. PubMed
70. de Lucía Finkel P, et al. 2021. Sci Rep. 11:12233. PubMed
71. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
72. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
73. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
74. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
75. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
76. Boeck M, et al. 2020. Glia. 1859:68. PubMed
77. Bersini S, et al. 2020. Life Sci Alliance. 3:e201900623. PubMed
78. Durré T, et al. 2018. Nat Commun. 9:5178. PubMed
79. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
80. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
81. Ma Z, et al. 2022. Methods Mol Biol. 2471:49. PubMed
82. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
83. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
84. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
85. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
86. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
87. Zhang P, et al. 2021. J Neuroinflammation. 18:215. PubMed
88. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
89. Wieghofer P, et al. 2021. EMBO J. 40:e105123. PubMed
90. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
91. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
92. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
93. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
94. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
95. Wakabayashi T et al. 2018. Cell stem cell. 22(3):384-397 . PubMed
96. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
97. Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed
98. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
99. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
100. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
101. Meng Michelle Xu et al. 2017. Immunity. 47(2):363-373 . PubMed
102. Süß P, et al. 2020. Cell Reports. 30(12):4082-4095. PubMed
103. Ombrato L, et al. 2021. Nat Protoc. 16:872. PubMed
104. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
105. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
106. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
107. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
108. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
109. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
110. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
111. Boddupalli CS, et al. 2022. Elife. 11:. PubMed
112. Palma A, et al. 2022. Front Cell Dev Biol. 10:841548. PubMed
113. Hu B, et al. 2020. J Clin Invest. 130:3483. PubMed
114. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
115. Nishimura T, et al. 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed
116. Usui-Ouchi A, et al. 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed
117. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
118. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
119. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
120. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed

RRID

AB_10899570 (BioLegend Cat. No. 103133)
AB_2562559 (BioLegend Cat. No. 103134)

Antigen Details

Structure

Protein tyrosine phosphatase (PTP) family, 180-240 kD

Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function

Phosphatase, T and B cell activation

Ligand/Receptor

Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1

Cell Type

B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs

Biology Area

Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID

19264 View all products for this Gene ID

UniProt

View information about CD45 on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats